<?xml version="1.0" ?>
<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2024//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_240101.dtd">
<PubmedArticleSet>
<PubmedArticle><MedlineCitation Status="PubMed-not-MEDLINE" Owner="NLM"><PMID Version="1">38020100</PMID><DateRevised><Year>2023</Year><Month>12</Month><Day>01</Day></DateRevised><Article PubModel="Electronic-eCollection"><Journal><ISSN IssnType="Print">2296-858X</ISSN><JournalIssue CitedMedium="Print"><Volume>10</Volume><PubDate><Year>2023</Year></PubDate></JournalIssue><Title>Frontiers in medicine</Title><ISOAbbreviation>Front Med (Lausanne)</ISOAbbreviation></Journal><ArticleTitle>Biologics targeting IL-17 and IL-23 maintain stability in patients with psoriasis during COVID-19 infection: a case-control study.</ArticleTitle><Pagination><StartPage>1280965</StartPage><MedlinePgn>1280965</MedlinePgn></Pagination><ELocationID EIdType="pii" ValidYN="Y">1280965</ELocationID><ELocationID EIdType="doi" ValidYN="Y">10.3389/fmed.2023.1280965</ELocationID><Abstract><AbstractText Label="BACKGROUND" NlmCategory="UNASSIGNED">Psoriasis is a chronic and refractory skin disease. The emergence of biologics provides more options for the treatment of psoriasis, but the COVID-19 pandemic poses challenges for the management of psoriasis.</AbstractText><AbstractText Label="OBJECTIVES" NlmCategory="UNASSIGNED">The purpose of this study was to investigate the effect of different biologics on the stabilization of psoriasis during COVID-19 infection in China.</AbstractText><AbstractText Label="METHODS" NlmCategory="UNASSIGNED">This is a single-center, observational, retrospective, case-control study. Using our database, we conducted a remote dermatologic study by means of questionnaire follow-up or telephone follow-up to collect general information of patients, information related to COVID-19 infection and conditions of psoriasis for comparison and further analysis between groups.</AbstractText><AbstractText Label="RESULTS" NlmCategory="UNASSIGNED">Our study ultimately included 274 patients for analysis. We found that the patients in this collection had mild symptoms of COVID-19 infection, and only 13 of them needed to go to the hospital for medical treatment. Further studies found that in biologics, relative to tumor necrosis factor-&#x3b1; inhibitors (TNF-&#x3b1;i), interleukin-17 inhibitors (IL-17i) and interleukin-23 inhibitors (IL-23i) are both protective factors in flare-up of psoriasis [IL-17i: OR (95% CI)&#x2009;=&#x2009;0.412 (0.189-0.901); IL-23i: OR (95% CI)&#x2009;=&#x2009;0.291 (0.097-0.876)]. In addition, we also found that the proportion of people with increased psoriasis developing long COVID-19 increased, and we speculated that increased psoriasis may be a potential risk factor for long COVID-19.</AbstractText><AbstractText Label="CONCLUSION" NlmCategory="UNASSIGNED">Our study showed that the use of IL-17i and IL-23i was a protective factor for psoriasis compared with TNF-&#x3b1;i, and could keep the psoriasis stable.</AbstractText><CopyrightInformation>Copyright &#xa9; 2023 Huang, Yu, Lu, Tan and Shi.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Huang</LastName><ForeName>Dawei</ForeName><Initials>D</Initials><AffiliationInfo><Affiliation>Shanghai Skin Disease Clinical College, Fifth Clinical Medical College, Anhui Medical University, Shanghai, China.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Dermatology, Shanghai Skin Disease Hospital, Tongji University, Shanghai, China.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Institute of Psoriasis, Tongji University School of Medicine, Shanghai, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Yu</LastName><ForeName>Yingyuan</ForeName><Initials>Y</Initials><AffiliationInfo><Affiliation>Department of Dermatology, Shanghai Skin Disease Hospital, Tongji University, Shanghai, China.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Institute of Psoriasis, Tongji University School of Medicine, Shanghai, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Lu</LastName><ForeName>Jiajing</ForeName><Initials>J</Initials><AffiliationInfo><Affiliation>Department of Dermatology, Shanghai Skin Disease Hospital, Tongji University, Shanghai, China.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Institute of Psoriasis, Tongji University School of Medicine, Shanghai, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Tan</LastName><ForeName>Fei</ForeName><Initials>F</Initials><AffiliationInfo><Affiliation>Shanghai Skin Disease Clinical College, Fifth Clinical Medical College, Anhui Medical University, Shanghai, China.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Dermatology, Shanghai Skin Disease Hospital, Tongji University, Shanghai, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Shi</LastName><ForeName>Yuling</ForeName><Initials>Y</Initials><AffiliationInfo><Affiliation>Shanghai Skin Disease Clinical College, Fifth Clinical Medical College, Anhui Medical University, Shanghai, China.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Dermatology, Shanghai Skin Disease Hospital, Tongji University, Shanghai, China.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Institute of Psoriasis, Tongji University School of Medicine, Shanghai, China.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2023</Year><Month>11</Month><Day>06</Day></ArticleDate></Article><MedlineJournalInfo><Country>Switzerland</Country><MedlineTA>Front Med (Lausanne)</MedlineTA><NlmUniqueID>101648047</NlmUniqueID><ISSNLinking>2296-858X</ISSNLinking></MedlineJournalInfo><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">COVID-19</Keyword><Keyword MajorTopicYN="N">SARS-COV-2</Keyword><Keyword MajorTopicYN="N">biologics</Keyword><Keyword MajorTopicYN="N">disease management</Keyword><Keyword MajorTopicYN="N">psoriasis</Keyword></KeywordList><CoiStatement>The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2023</Year><Month>8</Month><Day>21</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2023</Year><Month>10</Month><Day>25</Day></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2023</Year><Month>11</Month><Day>29</Day><Hour>18</Hour><Minute>44</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2023</Year><Month>11</Month><Day>29</Day><Hour>18</Hour><Minute>43</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2023</Year><Month>11</Month><Day>29</Day><Hour>14</Hour><Minute>39</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2023</Year><Month>11</Month><Day>6</Day></PubMedPubDate></History><PublicationStatus>epublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">38020100</ArticleId><ArticleId IdType="pmc">PMC10657819</ArticleId><ArticleId IdType="doi">10.3389/fmed.2023.1280965</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Griffiths C, Armstrong AW, Gudjonsson JE, Barker J. Psoriasis. Lancet. (2021) 397:1301&#x2013;15. doi: 10.1016/S0140-6736(20)32549-6</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S0140-6736(20)32549-6</ArticleId><ArticleId IdType="pubmed">33812489</ArticleId></ArticleIdList></Reference><Reference><Citation>Ghoreschi K, Balato A, Enerb&#xe4;ck C, Sabat R. Therapeutics targeting the il-23 and il-17 pathway in psoriasis. Lancet. (2021) 397:754&#x2013;66. doi: 10.1016/S0140-6736(21)00184-7</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S0140-6736(21)00184-7</ArticleId><ArticleId IdType="pubmed">33515492</ArticleId></ArticleIdList></Reference><Reference><Citation>Moltrasio C, Romagnuolo M, Marzano AV. Epigenetic mechanisms of epidermal differentiation. Int J Mol Sci. (2022) 23:23. doi: 10.3390/ijms23094874</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/ijms23094874</ArticleId><ArticleId IdType="pmc">PMC9102508</ArticleId><ArticleId IdType="pubmed">35563264</ArticleId></ArticleIdList></Reference><Reference><Citation>Kamiya K, Kishimoto M, Sugai J, Komine M, Ohtsuki M. Risk factors for the development of psoriasis. Int J Mol Sci. (2019) 20:20. doi: 10.3390/ijms20184347, PMID:</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/ijms20184347</ArticleId><ArticleId IdType="pmc">PMC6769762</ArticleId><ArticleId IdType="pubmed">31491865</ArticleId></ArticleIdList></Reference><Reference><Citation>Colombo D, Bianchi L, Fabbrocini G, Corrao S, Offidani A, Stingeni L, et al. . Real-world evidence of biologic treatments in moderate-severe psoriasis in Italy: results of the Canova (effectiveness of biologic treatments for plaque psoriasis in Italy: an observational longitudinal study of real-life clinical practice) study. Dermatol Ther. (2022) 35:e15166. doi: 10.1111/dth.15166, PMID:</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/dth.15166</ArticleId><ArticleId IdType="pubmed">34676662</ArticleId></ArticleIdList></Reference><Reference><Citation>Williamson EJ, Walker AJ, Bhaskaran K, Bacon S, Bates C, Morton CE, et al. . Factors associated with covid-19-related death using opensafely. Nature. (2020) 584:430&#x2013;6. doi: 10.1038/s41586-020-2521-4, PMID:</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41586-020-2521-4</ArticleId><ArticleId IdType="pmc">PMC7611074</ArticleId><ArticleId IdType="pubmed">32640463</ArticleId></ArticleIdList></Reference><Reference><Citation>Aram K, Patil A, Goldust M, Rajabi F. Covid-19 and exacerbation of dermatological diseases: a review of the available literature. Dermatol Ther. (2021) 34:e15113. doi: 10.1111/dth.15113, PMID:</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/dth.15113</ArticleId><ArticleId IdType="pmc">PMC8646294</ArticleId><ArticleId IdType="pubmed">34453380</ArticleId></ArticleIdList></Reference><Reference><Citation>Xu Q, Chen L, Li X, Zheng J. If skin is a potential host of SARS-cov-2, il-17 antibody could reduce the risk of covid-19. J Am Acad Dermatol. (2021) 84:e173. doi: 10.1016/j.jaad.2020.10.084, PMID:</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.jaad.2020.10.084</ArticleId><ArticleId IdType="pmc">PMC7642734</ArticleId><ArticleId IdType="pubmed">33159988</ArticleId></ArticleIdList></Reference><Reference><Citation>Elmas &#xd6;F, Demirba&#x15f; A, Kutlu &#xd6;, Ba&#x11f;c&#x131;er F, Metin MS, &#xd6;zyurt K, et al. . Psoriasis and covid-19: a narrative review with treatment considerations. Dermatol Ther. (2020) 33:e13858. doi: 10.1111/dth.13858, PMID:</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/dth.13858</ArticleId><ArticleId IdType="pmc">PMC7323009</ArticleId><ArticleId IdType="pubmed">32686245</ArticleId></ArticleIdList></Reference><Reference><Citation>Gelfand JM, Armstrong AW, Bell S, Anesi GL, Blauvelt A, Calabrese C, et al. . National psoriasis foundation covid-19 task force guidance for management of psoriatic disease during the pandemic: version 2-advances in psoriatic disease management, covid-19 vaccines, and covid-19 treatments. J Am Acad Dermatol. (2021) 84:1254&#x2013;68. doi: 10.1016/j.jaad.2020.12.058, PMID:</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.jaad.2020.12.058</ArticleId><ArticleId IdType="pmc">PMC7788316</ArticleId><ArticleId IdType="pubmed">33422626</ArticleId></ArticleIdList></Reference><Reference><Citation>Caroppo F, Fagotto L, Tartaglia J, Mazzetto R, Belloni FA. Impact of SARS-cov-2 infection in children with psoriasis: results of a monocentric experience. J Eur Acad Dermatol Venereol. (2023) 37:e570&#x2013;1. doi: 10.1111/jdv.18874</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/jdv.18874</ArticleId><ArticleId IdType="pubmed">36648141</ArticleId></ArticleIdList></Reference><Reference><Citation>Sbidian E, Chaimani A, Garcia-Doval I, do G, Hua C, Mazaud C, et al. . Systemic pharmacological treatments for chronic plaque psoriasis: a network meta-analysis. Cochrane Database Syst Rev. (2017) 12:CD011535. doi: 10.1002/14651858.CD011535.pub2, PMID:</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/14651858.CD011535.pub2</ArticleId><ArticleId IdType="pmc">PMC6486272</ArticleId><ArticleId IdType="pubmed">29271481</ArticleId></ArticleIdList></Reference><Reference><Citation>Deepak P, Kim W, Paley MA, Yang M, Carvidi AB, El-Qunni AA, et al. . Glucocorticoids and B Cell Depleting Agents Substantially Impair Immunogenicity of mRNA Vaccines to SARS-CoV-2. medRxiv [Preprint]. (2021).</Citation></Reference><Reference><Citation>Thatiparthi A, Martin A, Liu J, Egeberg A, Wu JJ. Biologic treatment algorithms for moderate-to-severe psoriasis with comorbid conditions and special populations: a review. Am J Clin Dermatol. (2021) 22:425&#x2013;42. doi: 10.1007/s40257-021-00603-w, PMID:</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s40257-021-00603-w</ArticleId><ArticleId IdType="pmc">PMC8051287</ArticleId><ArticleId IdType="pubmed">33861409</ArticleId></ArticleIdList></Reference><Reference><Citation>Lodde GC, Krefting F, Placke JM, Schneider L, Fiedler M, Dittmer U, et al. . Covid-19 vaccination in psoriasis patients receiving systemic treatment: a prospective single-center study. Front Immunol. (2023) 14:1107438. doi: 10.3389/fimmu.2023.1107438, PMID:</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fimmu.2023.1107438</ArticleId><ArticleId IdType="pmc">PMC10061348</ArticleId><ArticleId IdType="pubmed">37006279</ArticleId></ArticleIdList></Reference><Reference><Citation>Smail SW, Babaei E, Amin K, Abdulahad WH. Serum il-23, il-10, and tnf-&#x3b1; predict in-hospital mortality in covid-19 patients. Front Immunol. (2023) 14:1145840. doi: 10.3389/fimmu.2023.1145840</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fimmu.2023.1145840</ArticleId><ArticleId IdType="pmc">PMC10239952</ArticleId><ArticleId IdType="pubmed">37283736</ArticleId></ArticleIdList></Reference><Reference><Citation>Martonik D, Parfieniuk-Kowerda A, Starosz A, Grubczak K, Moniuszko M, Flisiak R. Effect of antiviral and immunomodulatory treatment on a cytokine profile in patients with covid-19. Front Immunol. (2023) 14:1222170. doi: 10.3389/fimmu.2023.1222170, PMID:</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fimmu.2023.1222170</ArticleId><ArticleId IdType="pmc">PMC10358833</ArticleId><ArticleId IdType="pubmed">37483627</ArticleId></ArticleIdList></Reference><Reference><Citation>L&#xf3;pez-Hern&#xe1;ndez Y, Mon&#xe1;rrez-Espino J, L&#xf3;pez D, Zheng J, Borrego JC, Torres-Calzada C, et al. . The plasma metabolome of long covid patients two years after infection. Sci Rep. (2023) 13:12420. doi: 10.1038/s41598-023-39049-x, PMID:</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41598-023-39049-x</ArticleId><ArticleId IdType="pmc">PMC10394026</ArticleId><ArticleId IdType="pubmed">37528111</ArticleId></ArticleIdList></Reference><Reference><Citation>Santopaolo M, Gregorova M, Hamilton F, Arnold D, Long A, Lacey A, et al. . Prolonged t-cell activation and long covid symptoms independently associate with severe covid-19 at 3 months. elife. (2023) 12:12. doi: 10.7554/eLife.85009</Citation><ArticleIdList><ArticleId IdType="doi">10.7554/eLife.85009</ArticleId><ArticleId IdType="pmc">PMC10319436</ArticleId><ArticleId IdType="pubmed">37310006</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle></PubmedArticleSet>